AstraZeneca PLC ã¯ãäžçäžã§ãè
«çåŠãå¿è¡ç®¡ãè
èããã³ä»£è¬ãåŒåžåšãææçãç¥çµç§åŠãæ¶ååšåŠã®åéã§åŠæ¹è¬ã®çºèŠãéçºã補é ã販売ãè¡ã£ãŠããŸããå瀟ã®åžè²©è£œåã«ã¯ãè
«çåŠçŸæ£çšã® TagrissoãLynparzaãImfinziãEnhertuãKoselugoãLumoxitiãEquidacentãZoladexãFaslodexãIressaãArimidexãCasodex/Cosudex ãªã©ãå¿è¡ç®¡ãè
èããã³ä»£è¬çŸæ£çšã® OnglyzaãBydureonãLokelmaãByettaãQternãSymlin ãªã©ãåŒåžåšããã³å
ç«çŸæ£çšã® SymbicortãPulmicortãFasenraãDaliresp/DaxasãDuaklirãTudorza/EkliraãBevespiãBreztriãAnifrolumab ãªã©ããããŸããå瀟ã¯ãŸããã·ããžã¹ããã«ãšã³ãºããã©/ãã«ãã¹ãã¯ã¢ããªãã¬ã³ããã»ãã¯ãšã«IR/ã»ãã¯ãšã«XRããã¢ããã¢ãã³ãã£ãã¯/ã¢ãã³ãã£ã°ãããã·ãŠã ããã»ãã¯/ããªãã»ãã¯ãã¢ã¹ãã©ãŒãã«ã®COVID-19ã¯ã¯ãã³ãªã©ããã®ä»ã®å»è¬åãCOVID-19補åãæäŸããŠããŸããå瀟ã¯ã販売代çåºãçŸå°ã®é§åšå¡äºåæãéããŠããã©ã€ããªã±ã¢å»ãšå°éå»ã«ãµãŒãã¹ãæäŸããŠããŸããå瀟ã¯ãæ é€èœå±€çްèè¡šé¢æå2ïŒTROP2ïŒè
«çã®æ²»çè¬DS-1062ã®éçºãšåååã§ç¬¬äžäžå
±ãšãé䟵襲æ§ã«ãªãŠã ã¢ãã¿ãªã³ã°ãœãªã¥ãŒã·ã§ã³ã®éçºã§ã¢ã©ã€ãã³ãŒç€Ÿãšãããžã¿ã«ãã«ã¹ãœãªã¥ãŒã·ã§ã³ã®å éã§ããµãã¥ãŒã»ããç·åç
é¢ãšãæ
¢æ§è
èç
ã«äŒŽãè²§è¡æ£è
ã®ãã¢ã°ããã³ç®¡çã®ããã®ã¹ããŒããã©ã³ã¢ããªã±ãŒã·ã§ã³ã®ç ç©¶ã§ãµã³ã®ããšãåç«è
ºããç ç©¶ã匷åããã¢ã«ã±ãããšãããŸããŸãªçš®é¡ã®ããã®æ²»çã®ããã®æ°ããäœååãçºèŠããã³éçºããããããã¹ãã€ãªã¹ãã©ã¯ãã£ãŒãºGmbHãšååå¥çŽãçµãã§ããŸããå瀟ã¯ä»¥å㯠Zeneca Group PLC ãšããŠç¥ãããŠããŸãããã1999 幎 4 æã« AstraZeneca PLC ã«ç€Ÿåã倿ŽããŸãããå瀟㯠Regeneron Pharmaceuticals, Inc. ãšååå¥çŽãçµã³ãè¥æºæ²»ççšã®äœååå»è¬åã®ç ç©¶ãéçºãåååãè¡ã£ãŠããŸããAstraZeneca PLC 㯠1992 幎ã«èšç«ãããè±åœã±ã³ããªããžã«æ¬ç€Ÿã眮ããŠããŸãã